<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 19 Aug 2026 13:30:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[Exyn Technologies (NASDAQ: EXYN)]]></title>
      <link>https://www.redchip.com/webinar/EXYN/82457691789</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/EXYN/82457691789</guid>
      <pubDate>Tue, 30 Jun 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Exyn Technologies is an autonomous robotics and geospatial intelligence company developing advanced software that enables drones, robots, and other autonomous systems to navigate, map, and collect high-value data in complex, GPS-denied environments. Built on its proprietary ExynAI autonomy platform, the Company delivers industrial-grade autonomous navigation and real-time 3D mapping solutions for customers across mining, infrastructure, construction, geospatial, and defense markets.]]></description>
    </item>
    <item>
      <title><![CDATA[Enlivex (NASDAQ: ENLV)]]></title>
      <link>https://www.redchip.com/webinar/ENLV/81583477307</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ENLV/81583477307</guid>
      <pubDate>Wed, 01 Jul 2026 15:00:00 +0000</pubDate>
      <description><![CDATA[Enlivex operates a dual-strategic corporate structure that combines clinical development in quality longevity therapeutics with a digital asset treasury strategy centered on the Rain prediction markets protocol. The first engine of this model is Allocetra™, Enlivex’s macrophage reprogramming immunotherapy platform. Allocetra™ is designed to restore immune balance by reprogramming dysregulated macrophages back to their homeostatic state. The therapy is being developed to address inflammatory and degenerative conditions associated with aging, including knee osteoarthritis and additional high-need indications. Positive clinical data in knee osteoarthritis have demonstrated meaningful reductions in pain and improvements in function across treated patients. The second engine of the Enlivex model is its RAIN-based digital asset treasury strategy. Through a $212 million private placement, Enlivex established the first public company treasury strategy centered on a decentralized prediction markets protocol. RAIN functions as a forecasting infrastructure where decentralized markets resolve real-world outcomes through token-based economic mechanisms, including a buyback-and-burn structure. Allocetra™ provides the biological value floor through clinical development in longevity therapeutics, while the RAIN treasury operates as the financial growth engine, giving Enlivex exposure to the expanding decentralized forecasting ecosystem through a Nasdaq-listed structure.]]></description>
    </item>
    <item>
      <title><![CDATA[The Metals Company (NASDAQ: TMC)]]></title>
      <link>https://www.redchip.com/webinar/TMC/87842220390</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/TMC/87842220390</guid>
      <pubDate>Wed, 15 Jul 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[The Metals Company is an explorer of lower-impact battery metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for the global energy transition with the least possible negative impacts on planet and people and (2) trace, recover and recycle the metals we supply to help create a metal commons that can be used in perpetuity. The Company through its subsidiaries holds exploration and commercial rights to three polymetallic nodule contract areas in the Clarion Clipperton Zone of the Pacific Ocean regulated by the International Seabed Authority and sponsored by the governments of Nauru, Kiribati, and the Kingdom of Tonga.]]></description>
    </item>
    <item>
      <title><![CDATA[Vertical Economy Investor Conference: The Race to Dominate the Skies]]></title>
      <link>https://www.redchip.com/webinar/redchip/87490314692</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/87490314692</guid>
      <pubDate>Thu, 16 Jul 2026 13:30:00 +0000</pubDate>
      <description><![CDATA[Vertical Economy Investor Conference: The Race to Dominate the Skies, RedChip’s virtual investor event, delivers direct access to publicly traded companies leading the transformation of airspace into the next great economic frontier. Discover innovators driving advancements in drones, eVTOL aircraft, aerospace systems, satellite infrastructure, and autonomous flight technologies.
Hear executives present their business models, technology breakthroughs, regulatory pathways, market opportunities, and competitive positioning, then engage with them directly through live Q&A.
Whether you're a retail investor seeking exposure to the rapidly expanding aerial economy or a professional evaluating emerging public-company opportunities in next-generation mobility and airspace innovation, this is your most focused, efficient path into the companies shaping the future above us.
Register today to secure your place.]]></description>
    </item>
    <item>
      <title><![CDATA[Nexalin Technology (NASDAQ: NXL)]]></title>
      <link>https://www.redchip.com/webinar/NXL/87940596953</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NXL/87940596953</guid>
      <pubDate>Tue, 28 Jul 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.]]></description>
    </item>
    <item>
      <title><![CDATA[BioVie (NASDAQ: BIVI)]]></title>
      <link>https://www.redchip.com/webinar/BIVI/82597296515</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BIVI/82597296515</guid>
      <pubDate>Wed, 29 Jul 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s lead drug candidate bezisterim inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer’s and Parkinson’s. Bezisterim is also being evaluated to treat the neurological symptoms associated with long COVID, which are associated with persistent systematic inflammation and neuroinflammation. In liver disease, the Company is actively exploring partnerships for a Phase 3 trial to evaluate BIV201 (continuous infusion terlipressin) to reduce further decompensation in participants with liver cirrhosis and ascites. BIV201 has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months.]]></description>
    </item>
    <item>
      <title><![CDATA[Comprehensive Healthcare Systems (OTCQB: CMHSF)]]></title>
      <link>https://www.redchip.com/webinar/CMHSF/83544332568</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/CMHSF/83544332568</guid>
      <pubDate>Tue, 18 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Following a multi-year operational restructuring and the installation of seasoned professional management, Comprehensive Healthcare Systems has transformed from a legacy, underinvested operator into a scalable, high-margin technology company with strong revenue visibility and accelerating momentum.]]></description>
    </item>
    <item>
      <title><![CDATA[Beyond the Index: The Next Generation of ETF Investing  ]]></title>
      <link>https://www.redchip.com/webinar/redchip/89581551123</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/89581551123</guid>
      <pubDate>Wed, 19 Aug 2026 13:30:00 +0000</pubDate>
      <description><![CDATA[RedChip's virtual investor conference, Beyond the Index: The Next Generation of ETF Investing, delivers direct access to the investment professionals driving innovation across the rapidly evolving ETF landscape. Discover funds and strategies designed to provide exposure to income-generating assets, thematic opportunities, active management approaches, alternative investments, and specialized market segments.   Hear portfolio managers and ETF sponsors discuss their investment philosophies, portfolio construction methodologies, market outlooks, and competitive advantages, then engage with them directly through live Q&A.   Whether you're a retail investor seeking innovative ways to build and diversify your portfolio or a professional evaluating emerging investment strategies and market opportunities, this is your most focused, efficient path into the next generation of ETF investing. 
Register today to secure your place.]]></description>
    </item>
  </channel>
</rss>
